CHIR-090 | 728865-23-4

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: CHIR-090
• 英文别名: N-{(1s,2r)-2-Hydroxy-1-[(Hydroxyamino)carbonyl]propyl}-4-{[4-(Morpholin-4-Ylmethyl)phenyl]ethynyl}benzamide；N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[2-[4-(morpholin-4-ylmethyl)phenyl]ethynyl]benzamide
• CAS: 728865-23-4
• 化学式: C₂₄H₂₇N₃O₅
• 分子量: 437.495
• InChiKey: FQYBTYFKOHPWQT-VGSWGCGISA-N

物化性质

• 密度：
  1.33±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO 中≥21.85 mg/mL；不溶于乙醇；不溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  111
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 危险类别：
  4.1
• 危险性防范说明：
  P240,P210,P241,P264,P280,P302+P352,P370+P378,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险品运输编号：
  1325
• 危险性描述：
  H315,H319,H228
• 包装等级：
  II

反应信息

• 作为产物：
  描述：

  4-乙炔基苯甲酸钠 在 potassium cyanide 、 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 羟胺 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 水 、 溶剂黄146 为溶剂， 反应 44.08h， 生成 CHIR-090
  参考文献：
  名称：

  Exploring the UDP pocket of LpxC through amino acid analogs

  摘要：

  Lipopolysaccharide (LPS) biosynthesis is an attractive antibacterial target as it is both conserved and essential for the survival of key pathogenic bacteria. Lipid A is the hydrophobic anchor for LPS and a key structural component of the outer membrane of Gram-negative bacteria. Lipid A biosynthesis is performed in part by a unique zinc dependent metalloamidase, LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase), which catalyzes the first non-reversible step in lipid A biosynthesis. The UDP portion of the LpxC substrate-binding pocket has been relatively unexplored. We have designed and evaluated a series of hydroxamate based inhibitors which explore the SAR of substitutions directed into the UDP pocket with a range of substituted α-amino acid based linkers. We also provide the first wild type structure of Pseudomonas aeruginosa LpxC which was utilized in the design of many of these analogs.

  DOI：

  10.1016/j.bmcl.2013.02.055

文献信息

• ANTIBACTERIAL AGENTS
  申请人：Andersen Niels H.

  公开号：US20080269221A1

  公开（公告）日：2008-10-30

  Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供化学式I的抗菌化合物：以及立体异构体，药学上可接受的盐，酯和前药; 包含这些化合物的制药组合物; 通过给予这些化合物的途径治疗细菌感染的方法; 以及制备这些化合物的工艺。
• ETHYNYLBENZENE DERIVATIVES
  申请人：Zhou Pei

  公开号：US20130231323A1

  公开（公告）日：2013-09-05

  Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R 1 , R 2 , R 3 , R 101 , L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

  本发明涉及式(I)、(II)和(II)I的化合物及其药学上可接受的盐，其中变量R、R1、R2、R3、R101、L、D、Q、Y、X和Z的定义如下。这些化合物可用于治疗革兰氏阴性菌感染。
• Antibacterial Agents
  申请人：Andersen Niels H.

  公开号：US20100324025A1

  公开（公告）日：2010-12-23

  Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供公式I的抗菌化合物：以及其对映异构体，药学上可接受的盐，酯和前药；包含这些化合物的制药组合物；通过给予这些化合物的途径治疗细菌感染的方法；以及制备这些化合物的过程。
• CONTRAST AGENTS BASED ON LONG-LIVED NUCLEAR SINGLET STATES AND RELATED METHODS
  申请人：Duke University

  公开号：US20150064113A1

  公开（公告）日：2015-03-05

  Methods are described for preparing magnetic resonance imaging (MRI) and/or magnetic resonance spectroscopy contrast agents where the contrast agents are prepared from precursor molecules having at least four non-zero-spin nuclei that form two pairs of chemically equivalent or effectively equivalent nuclei, e.g., diphenylacetylene or diethyl oxalate. The precursor molecule is hyperpolarized and a sequence of one or more radiofrequency pulses is applied to transfer spin state population between the first and second pair of nuclei, thereby providing a non-equilibrium single state nuclear spin population. To detect the contrast agent, another sequence of one or more radiofrequency pulses is applied to transfer singlet order to polarization. No transformation of the molecular structure of the contrast agent is necessary for detection. Also described are methods of imaging targets using the contrast agents.

  本文描述了制备磁共振成像（MRI）和/或磁共振波谱学对比剂的方法，其中对比剂是由至少四个非零自旋核形成的前体分子制备而成，这些核形成两对化学等价或有效等价的核，例如二苯乙炔或草酸二乙酯。前体分子被超极化，然后应用一个或多个无线电频率脉冲序列来在第一对核和第二对核之间转移自旋状态，从而提供非平衡单态核自旋种群。为了检测对比剂，另一个或多个无线电频率脉冲序列被应用来将单态序转移到极化。不需要对比剂的分子结构进行转换以进行检测。还描述了使用对比剂成像目标的方法。
• COMPOUND ACTING AS ANTIBIOTICS
  申请人：KBP Biosciences Co., Ltd.

  公开号：EP3750881A1

  公开（公告）日：2020-12-16

  The present invention provides a novel antibiotic compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof. The compound of the present invention exhibits excellent antibacterial activity, especially against Gram bacteria. wherein each group is defined as in the description.

  本发明提供了一种由下式（I）表示的新型抗生素化合物、其药学上可接受的盐、酯、原药、溶液或其氘代类似物或其立体异构体。本发明的化合物具有优异的抗菌活性，特别是对革兰氏细菌。 其中各基团的定义与说明中的相同。